Revenue Growth
Consolidated revenue of $265 million, up $18 million or 7% year-over-year (from $247 million). On a constant currency basis revenue grew $11 million or 4%. Revenue increases were reported in both Print and Advanced Materials & Chemicals (AM&C).
Gross Profit Improvement
Gross profit of $57 million, up $11 million or 24% year-over-year. Gross profit percentage increased to 22% from 19% in the prior-year quarter (an increase of 3 percentage points, ~16% higher).
Operational EBITDA Surge
Operational EBITDA of $15 million versus $2 million in Q1 2025, an increase of $13 million driven primarily by improved pricing and operational execution (partially offset by higher manufacturing and commodity costs).
AM&C and Film Momentum
AM&C revenue grew $2 million or 3%, driven by a $3 million increase in film and chemicals (partially offset by $1 million lower inks/consumables). New product momentum includes a professional still film sold to distributors and launch of Virita 200D (used in Euphoria season 3); company film was used on multiple high-profile productions.
Commercial Print Resilience and Product Expansion
Commercial print revenue increased 9% despite raw material pressure. Launched Sonora Ultra XR Plate in Europe to expand Sonora Ultra portfolio and maintained supply to customers amid challenging market conditions.
Pharma & R&D Investments
CGMP pharmaceutical manufacturing facility is up and running. Opened Advanced Electrophysiology Lab with SUNY Geneseo to enhance research capabilities and support product development; working toward Class II certification to manufacture more complex, higher-margin U.S. products.
Balance Sheet Progress and Deleveraging
Unrestricted cash of $299 million and a net debt positive position improved from $128 million to $139 million (an $11 million improvement). Paid $50 million principal on higher-rate term loans and reported the third consecutive quarter of year-over-year growth in revenue, gross profit, and operational EBITDA.